Tissue profiling by MALDI mass spectrometry distinguishes clinical grades of soft tissue sarcomas

Cancer Genomics and Proteomics

Volumn 2, Issue 6, 2005, Pages 333-345

  Caldwell, Robert L ^a,b   Holt, Ginger E ^a   Caprioli, Richard M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medical Center East   (United States)

Author keywords

Biomarker; MALDI mass spectrometry; Proteomics; Soft tissue sarcoma; Tissue profiling

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MESENCHYMOMA; SOFT TISSUE SARCOMA; TUMOR CLASSIFICATION;

EID: 30044442814     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
2. Pisters P: American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Edited by Pollock RE. Hamilton, Ontario, BC Decker, pp. 80-88, 2002.
3. Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin 54: 94-109, 2004.
4. DeVita VT Jr and Rosenberg SA: Cancer: Principles and Practice of Oncology. Edited by Philadelphia, Lippincott Williams & Wilkins, pp. 1841-1891, 2001.
5. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, Sastre X, Vilain MO, Bonichon F and N' Guyen Bui B: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91: 1914-1926, 2001.
6. Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG, Meissner W, Miller WT, Schmitz RL and Suit HD: A clinical and pathological staging system for soft tissue sarcomas. Cancer 40: 1562-1570, 1977.
7. Singer S: New diagnostic modalities in soft tissue sarcoma. Sem Surg Oncol 17: 11-22, 1999.
8. Shiraki M, Enterline HT, Brooks JJ, Cooper NS, Hirschl S, Roth JA, Rao UN, Enzinger FM, Amato DA and Borden EC: Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 64: 484-490, 1989.
9. Presant CA, Russell WO, Alexander RW and Fu YS: Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. J Clin Oncol 4: 1658-1661, 1986.
10. Alvegard TA and Berg NO: Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 7: 1845-1851, 1989.
11. Fletcher DM, Unni KK and Mertens F: World Health Organization Classification of Tumors: Pathology and genetics of tumours of soft tissue and bone. Edited by Washington, D.C., IARC Press, 2002.
12. Chaurand P, Stoeckli M and Caprioli RM: Direct profiling of proteins in biological tissue sections by MALDI mass spectrometry. Anal Chem 71: 5263-5270, 1999.
13. Zheng Y, Xu Y, Ye B, Lei J, Weinstein MH, O'Leary MP, Richie JP, Mok SC and Liu BC: Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98: 2576-2582, 2003.
14. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW and Caprioli RM: Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 1: 1320-1326, 2001.
15. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM and Carbone DP: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362: 433-439, 2003.
16. Chaurand P, Schwartz SA, Billheimer D, Xu BJ, Crecelius A and Caprioli RM: Integrating histology and imaging mass spectrometry. Anal Chem 76: 1145-1155, 2004.
17. Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL and Caprioli RM: Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64: 9093-9100, 2004.
18. Ham AJ, Jones JA and Liebler DC: CHIPS (Complete Hierarchical Integration of Protein Searches), a database program for storing, filtering and comparing Sequest outputs. Edited by Nashville, TN, USA, 2004.
19. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD and Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
20. Kachigan SK: Multivariate Statistical Analysis: A Conceptual Introduction. Edited by Marylan: Radius Press, 1991.
21. Schwartz SA: Proteomic-based Classification of Human Brain Tumors by Mass Spectrometry. Edited by Nashville, Vanderbilt University, pp. 139, 2004.
22. Campa MJ, Wang MZ, Howard B, Fitzgerald MC and Patz EF Jr: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 63: 1652-1656, 2003.
23. Chaurand P, Sanders ME, Jensen RA and Caprioli RM: Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 165: 1057-1068, 2004.
24. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB and Matusik RJ: A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61: 2239-2249, 2001.
25. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA and Caprioli RM: Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 38: 1081-1092, 2003.
26. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP and Lemoine NR: Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201: 63-74, 2003.
27. 2+ binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 36: 1050-1059, 2000.
28. Schafer BW, Wicki R, Engelkamp D, Mattei MG and Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25: 638-643, 1995.
29. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668, 2001.
30. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C and Illmensee K: Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 63: 7507-7514, 2003.
31. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M and Hamdy FC: Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64: 1238-1243, 2004.
32. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M and Fan ST: Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107: 22-29, 2003.
33. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A and Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759, 1993.
34. Calandra T, Bernhagen J, Mitchell RA and Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902, 1994.
35. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A and Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71, 1995.
36. Mitchell RA and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Sem Cancer Biol 10: 359-366, 2000.
37. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382, 1999.
38. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M and Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758, 1999.
39. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF and Tosi P: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18: 2832-2841, 1997.
40. Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48: 448-452, 1996.
41. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T and Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89: 334-341, 2000.
42. Diffee GM, Kalfas K, Al-Majid S and McCarthy DO: Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 283: 1376-1382, 2002.
43. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S and Guttridge DC: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114: 370-378, 2004.
44. Madhavan M and Krishnan KB: Cell marker studies in undifferentiated soft tissue sarcoma. Indian J Pathol Microbiol 34: 99-103, 1991.
45. Schmidt D, Reimann O, Treuner J and Harms D: Cellular differentiation and prognosis in embryonal rhabdomyosarcoma. A report from the Cooperative Soft Tissue Sarcoma Study 1981 (CWS 81). Virchows Arch A Pathol Anat Histopathol 409: 183-194, 1986.
46. Pawel BR, Hamoudi AB, Asmar L, Newton WA, Jr., Ruymann FB, Qualman SJ, Webber BL and Maurer HM: Undifferentiated sarcomas of children: pathology and clinical behavior-an Intergroup Rhabdomyosarcoma study. Med Pediatr Oncol 29: 170-180, 1997.
47. Anagnostopoulos G, Sakorafas GH, Grigoriadis K and Kostopoulos P: Malignant fibrous histiocytoma of the liver: a case report and review of the literatures. Mt Sinai J Med 72: 50-52, 2005.
48. Prasad S, Soldatenkov VA, Srinivasarao G and Dritschilo A: Intermediate filament proteins during carcinogenesis and apoptosis (Review). Int J Oncol 14: 563-570, 1999.
49. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnolzer M, Sinha P and Federici G: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005.
50. Byun Y, Chen F, Chang R, Trivedi M, Green KJ and Cryns VL: Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8: 443-450, 2001.
51. Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R and Seibel MJ: Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 46: 684-690, 2000.